NASDAQ
SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a new 55 mg pre-filled syri...
Healthcare stocks outperformed the broader market on Friday, with Eli Lilly (LLY), Johnson and Johnson (JNJ) and AbbVie (ABBV) among the major names hitting fresh...
NORTH CHICAGO, Ill., June 26, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2026 financial results on Friday, July 31, 2026, before the market opens....
AbbVie is aggressively expanding its pipeline to offset the impact of biosimilar competition for its top-selling drugs. Pfizer is utilizing substantial capital for acquisitions to diversify its revenu...
The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?...
Large-cap pharma is back in the deal market. AbbVie's (NASDAQ: ABBV | ABBV Price Prediction) pending acquisition of Apogee Therapeutics signaled that big buyers will pay up for de-risked clinical asse...
I hit the buy button on AbbVie (NYSE:ABBV | ABBV Price Prediction) again last week, and I will hit it again the next time June's macro noise hands me a discount....
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propo...
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apoge...
In this week's edition of InnovationRx, we look at AbbVie's new megadeal, an agentic AI startup saving Medicare $2 million a week, how new student loan rules could degrade healthcare and more. To get ...
No price data available for this timeframe.